Work

Eficácia de esquemas terapêuticos baseados em bloqueadores competitivos de potássio (P-CABS) na erradicação de cepas de Helicobacter pylori resistentes

Year: 2026
Type: article
Abstract: Helicobacter pylori infection is a severe public health issue, characterized by high prevalence in Latin America and a strong association with the development of gastric cancer. Given the growing bacterial resistance to conventional therapy based on proton pump inhibitors (PPIs), potassium-competitive acid blockers (P-CABs) emerge as a promising alternative. The present study aims to evaluate the efficacy of P-CABs, focusing on vonoprazan and tegoprazan, in the eradication of resistant H. pylori strains compared to PPIs. To this end, a literature review was conducted in the PubMed/MEDLINE, Embase, Cochrane, and Web of Science databases, encompassing publications particularly from the last 10 years. The results indicate that P-CABs promote faster, more potent, and sustained acid suppression without being subjected to interference from CYP2C19 polymorphisms. Vonoprazan-based regimens achieve overall eradication rates of 86% to 94%, outperforming PPIs, especially in clarithromycin-resistant strains (66% to 81% efficacy against 32% to 40% for PPIs). Highdose vonoprazan dual therapy stood out for its high efficacy and lower incidence of adverse events. Thus, it is concluded that P-CABs represent a significant therapeutic advance, offering greater reliability in combating antimicrobial resistance. However, due to the scarcity of robust data on Latin American populations, future regional clinical trials and cost-effectiveness evaluations tailored to the reality of the Brazilian healthcare system become essential to substantiate new clinical guidelines.
Language: English
Field: Medicine
Open Access status: diamond
OpenAlex ID: W7236968657
FWCI:
Cites: 30
Cited by:
Related to: 10